VTYX Quote, Financials, Valuation and Earnings

Genprex, Inc. has a net margin of -- compared to Ventyx Biosciences, Inc.'s net margin of --. Ventyx Biosciences, Inc.'s return on equity of -45.75% beat Genprex, Inc.'s return on equity of -900.4%.

Ventyx Biosciences, Inc. has a consensus price target of $15.14, signalling upside risk potential of 84.9%. On the other hand Genprex, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 13104.23%. Given that Genprex, Inc. has higher upside potential than Ventyx Biosciences, Inc., analysts believe Genprex, Inc. is more attractive than Ventyx Biosciences, Inc..

Ventyx Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genprex, Inc. has a beta of -0.771, suggesting its less volatile than the S&P 500 by 177.148%.

Ventyx Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genprex, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ventyx Biosciences, Inc. pays -- of its earnings as a dividend. Genprex, Inc. pays out -- of its earnings as a dividend.

Ventyx Biosciences, Inc. quarterly revenues are --, which are smaller than Genprex, Inc. quarterly revenues of --. Ventyx Biosciences, Inc.'s net income of -$22.8M is lower than Genprex, Inc.'s net income of -$3.8M. Notably, Ventyx Biosciences, Inc.'s price-to-earnings ratio is -- while Genprex, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ventyx Biosciences, Inc. is -- versus -- for Genprex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -- compared to Ventyx Biosciences, Inc.'s net margin of -19.69%. Ventyx Biosciences, Inc.'s return on equity of -45.75% beat Moderna, Inc.'s return on equity of -30.18%.

Ventyx Biosciences, Inc. has a consensus price target of $15.14, signalling upside risk potential of 84.9%. On the other hand Moderna, Inc. has an analysts' consensus of $35.37 which suggests that it could grow by 20.41%. Given that Ventyx Biosciences, Inc. has higher upside potential than Moderna, Inc., analysts believe Ventyx Biosciences, Inc. is more attractive than Moderna, Inc..

Ventyx Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Ventyx Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ventyx Biosciences, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Ventyx Biosciences, Inc. quarterly revenues are --, which are smaller than Moderna, Inc. quarterly revenues of $1B. Ventyx Biosciences, Inc.'s net income of -$22.8M is higher than Moderna, Inc.'s net income of -$200M. Notably, Ventyx Biosciences, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ventyx Biosciences, Inc. is -- versus 5.11x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Neumora Therapeutics, Inc. has a net margin of -- compared to Ventyx Biosciences, Inc.'s net margin of --. Ventyx Biosciences, Inc.'s return on equity of -45.75% beat Neumora Therapeutics, Inc.'s return on equity of -102.63%.

Ventyx Biosciences, Inc. has a consensus price target of $15.14, signalling upside risk potential of 84.9%. On the other hand Neumora Therapeutics, Inc. has an analysts' consensus of $9.17 which suggests that it could grow by 338.6%. Given that Neumora Therapeutics, Inc. has higher upside potential than Ventyx Biosciences, Inc., analysts believe Neumora Therapeutics, Inc. is more attractive than Ventyx Biosciences, Inc..

Ventyx Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Neumora Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ventyx Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neumora Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ventyx Biosciences, Inc. pays -- of its earnings as a dividend. Neumora Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ventyx Biosciences, Inc. quarterly revenues are --, which are smaller than Neumora Therapeutics, Inc. quarterly revenues of --. Ventyx Biosciences, Inc.'s net income of -$22.8M is higher than Neumora Therapeutics, Inc.'s net income of -$56.8M. Notably, Ventyx Biosciences, Inc.'s price-to-earnings ratio is -- while Neumora Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ventyx Biosciences, Inc. is -- versus -- for Neumora Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -- compared to Ventyx Biosciences, Inc.'s net margin of --. Ventyx Biosciences, Inc.'s return on equity of -45.75% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Ventyx Biosciences, Inc. has a consensus price target of $15.14, signalling upside risk potential of 84.9%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 151.86%. Given that Viking Therapeutics, Inc. has higher upside potential than Ventyx Biosciences, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Ventyx Biosciences, Inc..

Ventyx Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Ventyx Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ventyx Biosciences, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ventyx Biosciences, Inc. quarterly revenues are --, which are smaller than Viking Therapeutics, Inc. quarterly revenues of --. Ventyx Biosciences, Inc.'s net income of -$22.8M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Ventyx Biosciences, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ventyx Biosciences, Inc. is -- versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.